Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
OX2 Therapeutics
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Aged 18 years and older.
Confirmed diagnosis of GBM.
Radiographically or histologically proven progression or recurrence of disease at any time after standard of care therapy (radiation, temozolomide, with or without a tumor treatment field device).
Tumor debulking or biopsies may be performed to clinical trial enrollment if indicated and feasible.
You may not be if
Bevacizumab or targeted therapy within 45 days of enrollment.
Intercurrent immune system disorder such as hypoimmunity (marrow failure, HIV) or hyperimmunity (autoimmune disease).
Unable to complete a standard upfront course of chemoradiotherapy due to disease progression or intolerance of therapy.
History of Gliadel water, GammaTile or other implanted therapeutic agent.
Concurrent use of tumor treatment field devices (e.g. Optune).
Clareo Health | Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma
